Circulating Levels of Glial Cell Line-Derived Neurotrophic Factor (GDNF) in Schizophrenia: a Systematic Review and Meta-analysis

Overview

Journal BMC Psychiatry

Publisher Biomed Central

Date 2025 Jan 29

PMID 39881227

Authors

Omran Davarinejad

Saeid Komasi

Mohammad-Taher Moradi

Farzaneh Golmohammadi

Maryam Bahrami

Hamed Esmaeil Lashgarian

Masumeh Jalalvand

Sara Hookari

Fatemeh Kazemisafa

Affiliations

Soon will be listed here.

Abstract

Background: Glial cell line-derived neurotrophic factor (GDNF) has emerged as a potential biomarker for schizophrenia (SCZ). However, GDNF levels remain unclear in affected individuals compared to healthy controls. Therefore, we aimed to calculate a pooled estimate of GDNF levels in patients with SCZ in comparison with healthy controls.

Methods: A systematic search was performed in PubMed, Scopus, Web of Science, and Science Direct for published studies from the first date available up to 17 June 2024. Twelve studies (n = 817 patients and 691 healthy controls) were included in the meta-analysis. Subgroup analyses and meta-regression were performed, addressing heterogeneity and publication bias.

Results: Random-effects estimates (d = -0.80, p < 0.001) of the present meta-analysis revealed a significant mean difference in GDNF levels between SCZ patients and healthy controls. Subgroup analyses indicated that the standardized mean difference of GDNF was larger in European samples (d = -1.01, p ≤ 0.001) than in the Asian population (d = -0.61, p = 0.011). Non-medicated SCZ patients (d = -1.08, p ≤ 0.001) exhibited lower GDNF levels than those on medication (d = - 0.70, p = 0.004). Additionally, patients with a disease duration of ≥ 10 years showed lower levels of GDNF (d = -0.93, p = 0.058 versus d = -0.82, p = 0.002).

Conclusions: The findings suggested that GDNF may be a promising biomarker and therapeutic target for schizophrenia. Future research should focus on elucidating the mechanisms underlying altered GDNF levels and exploring its implications for treatment strategies.

References

Duarte E, Curcio M, Canzoniero L, Duarte C . Neuroprotection by GDNF in the ischemic brain. Growth Factors. 2012; 30(4):242-57. DOI: 10.3109/08977194.2012.691478. View

Ye F, Zhan Q, Xiao W, Sha W, Zhang X . Altered serum levels of glial cell line-derived neurotrophic factor in male chronic schizophrenia patients with tardive dyskinesia. Int J Methods Psychiatr Res. 2018; 27(4):e1727. PMC: 6877127. DOI: 10.1002/mpr.1727. View

Davarinejad O, Najafi S, Zhaleh H, Golmohammadi F, Radmehr F, Alikhani M . MiR-574-5P, miR-1827, and miR-4429 as Potential Biomarkers for Schizophrenia. J Mol Neurosci. 2021; 72(2):226-238. DOI: 10.1007/s12031-021-01945-0. View

Takahashi M . The GDNF/RET signaling pathway and human diseases. Cytokine Growth Factor Rev. 2001; 12(4):361-73. DOI: 10.1016/s1359-6101(01)00012-0. View

Lin P, Tseng P . Decreased glial cell line-derived neurotrophic factor levels in patients with depression: a meta-analytic study. J Psychiatr Res. 2015; 63:20-7. DOI: 10.1016/j.jpsychires.2015.02.004. View

Airaksinen M, Saarma M . The GDNF family: signalling, biological functions and therapeutic value. Nat Rev Neurosci. 2002; 3(5):383-94. DOI: 10.1038/nrn812. View

Maheu M, Lopez J, Crapper L, Davoli M, Turecki G, Mechawar N . MicroRNA regulation of central glial cell line-derived neurotrophic factor (GDNF) signalling in depression. Transl Psychiatry. 2015; 5:e511. PMC: 4445749. DOI: 10.1038/tp.2015.11. View

Safari R, Tunca Z, Ozerdem A, Ceylan D, Yalcin Y, Sakizli M . Glial cell-derived neurotrophic factor gene polymorpisms affect severity and functionality of bipolar disorder. J Integr Neurosci. 2017; 16(4):471-481. DOI: 10.3233/JIN-170031. View

Ibanez C, Andressoo J . Biology of GDNF and its receptors - Relevance for disorders of the central nervous system. Neurobiol Dis. 2016; 97(Pt B):80-89. DOI: 10.1016/j.nbd.2016.01.021. View

10.

Pang L, Li X, Yuan X, Hei G, Zhang L, Wang S . [Establishment of diagnostic model for schizophrenia based on neurotrophic factor and other biomarkers]. Zhonghua Yi Xue Za Zhi. 2023; 103(17):1310-1315. DOI: 10.3760/cma.j.cn112137-20221212-02631. View

11.

Runeberg-Roos P, Penn R . Improving therapeutic potential of GDNF family ligands. Cell Tissue Res. 2020; 382(1):173-183. PMC: 7529618. DOI: 10.1007/s00441-020-03256-z. View

12.

Marshall P . Finding an Optimal Level of GDNF Overexpression: Insights from Dopamine Cycling. Cell Mol Neurobiol. 2023; 43(7):3179-3189. PMC: 10477250. DOI: 10.1007/s10571-023-01375-z. View

13.

Fisar Z . Biological hypotheses, risk factors, and biomarkers of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2022; 120:110626. DOI: 10.1016/j.pnpbp.2022.110626. View

14.

Gerlai R, McNamara A, Choi-Lundberg D, Armanini M, Ross J, PHILLIPS H . Impaired water maze learning performance without altered dopaminergic function in mice heterozygous for the GDNF mutation. Eur J Neurosci. 2001; 14(7):1153-63. DOI: 10.1046/j.0953-816x.2001.01724.x. View

15.

Li X, Wei N, Song J, Liu J, Yuan J, Song R . The global burden of schizophrenia and the impact of urbanization during 1990-2019: An analysis of the global burden of disease study 2019. Environ Res. 2023; 232:116305. DOI: 10.1016/j.envres.2023.116305. View

16.

Orth S, Ritz E, Suter-Crazzolara C . Glial cell line-derived neurotrophic factor (GDNF) is expressed in the human kidney and is a growth factor for human mesangial cells. Nephrol Dial Transplant. 2000; 15(5):589-95. DOI: 10.1093/ndt/15.5.589. View

17.

Xiao W, Ye F, Liu C, Tang X, Li J, Dong H . Cognitive impairment in first-episode drug-naïve patients with schizophrenia: Relationships with serum concentrations of brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor. Prog Neuropsychopharmacol Biol Psychiatry. 2017; 76:163-168. DOI: 10.1016/j.pnpbp.2017.03.013. View

18.

Mesa-Infante V, Afonso-Oramas D, Salas-Hernandez J, Rodriguez-Nunez J, Barroso-Chinea P . Long-term exposure to GDNF induces dephosphorylation of Ret, AKT, and ERK1/2, and is ineffective at protecting midbrain dopaminergic neurons in cellular models of Parkinson's disease. Mol Cell Neurosci. 2021; 118:103684. DOI: 10.1016/j.mcn.2021.103684. View

19.

Turkmen B, Yazici E, Erdogan D, Suda M, Yazici A . BDNF, GDNF, NGF and Klotho levels and neurocognitive functions in acute term of schizophrenia. BMC Psychiatry. 2021; 21(1):562. PMC: 8588660. DOI: 10.1186/s12888-021-03578-4. View

20.

Kotyuk E, Keszler G, Nemeth N, Ronai Z, Sasvari-Szekely M, Szekely A . Glial cell line-derived neurotrophic factor (GDNF) as a novel candidate gene of anxiety. PLoS One. 2013; 8(12):e80613. PMC: 3855631. DOI: 10.1371/journal.pone.0080613. View